Paratek Pharmaceuticals, Inc. Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from Q2 2016 to Q2 2023
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
Paratek Pharmaceuticals, Inc. quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from Q2 2016 to Q2 2023.
- Paratek Pharmaceuticals, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending June 30, 2023 was -$14.5M, a 17.7% increase year-over-year.
- Paratek Pharmaceuticals, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was -$63.5M, a 8.59% decline from 2021.
- Paratek Pharmaceuticals, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2021 was -$58.5M, a 39.4% increase from 2020.
- Paratek Pharmaceuticals, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2020 was -$96.5M, a 24.9% increase from 2019.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Growth (%)